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Abstract: Prion diseases or Transmissible Spongiform Encephalopathies (TSEs) are lethal 
neurodegenerative disorders involving the misfolding of the host encoded cellular prion 
protein, PrP
C
. This physiological form of the protein is expressed throughout the body, and 
it reaches the highest levels in the central nervous system where the pathology occurs. The 
conversion into the pathogenic isoform denoted as prion or PrP
Sc
 is the key event in prion 
disorders. Prominent candidates for the treatment of prion diseases are antibodies and their 
derivatives. Anti-PrP
C
 antibodies are able to clear PrP
Sc
 from cell culture of infected cells. 
Furthermore, application of anti-PrP
C
 antibodies suppresses prion replication in experimental 
animal models. Major drawbacks of immunotherapy are immune tolerance, the risks of 
neurotoxic side effects, limited ability of compounds to cross the blood-brain barrier and 
their unfavorable pharmacokinetic. The focus of this review is to recapitulate the current 
understanding of the molecular mechanisms for antibody mediated anti-prion activity. 
Although relevant for designing immunotherapeutic tools, the characterization of key 
antibody parameters shaping the molecular mechanism of the PrP
C
 to PrP
Sc
 conversion 
remains elusive. Moreover, this review illustrates the various attempts towards the 
development of anti-PrP antibody compounds and discusses therapeutic candidates that 
modulate PrP expression. 
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1. Introduction 
Prion diseases, or Transmissible Spongiform Encephalopathies (TSEs), represent a group of lethal 
neurodegenerative diseases. In addition to humans, several mammalian species may develop TSE, 
including Bovine Spongioform Encelopathy (BSE) in cattle, scrapie in sheep and goat or Chronic 
Wasting Diseases (CWD) in deer, moose and elk [1]. Certain types of the disease can be transmitted 
from human to human, such as Kuru or iatrogenic CJD (iCJD); but also from animals to humans, 
where the most prominent example is BSE in variant Cruetzfeldt-Jacob Disease (vCJD), mostly 
acquired through the consumption of BSE-infected food. However, less than 5% of prion-caused 
diseases are acquired, 10% to 15% are defined as genetic, while the remaining majority are considered 
sporadic [2]. Genetic types of the disease in humans are familial CJD (fCJD), fatal familial insomnia 
(FFI), prion protein cerebral angiopathy (PrP CAA) and Gerstmann–Sträussler–Scheinker syndrome 
(GSS), while sporadic types include sporadic CJD (sCJD), sporadic fatal insomnia and variably 
protease-sensitive prionopathy (VPSPr) [3], the most recently identified prionopathy [4]. 
These diseases have a long asymptomatic incubation period and largely differ in their clinical 
course, which typically ranges from a few months to several years. What is common is that all are 
triggered by misfolding of a host encoded cellular prion protein (PrP
C
) [5]. All TSEs share common 
neurodegenerative features: aggregation of the misfolded PrP
C
, early synaptic dysfunction and 
irreversible death of neurons [6]. PrP
C
 is physiologically expressed throughout the body and is highly 
expressed in the central (CNS) and peripheral (PNS) nervous system, as a normal part of the neuronal 
membrane. It has a complex intracellular trafficking that seems to depend on the cell type [7]. The 
development of TSE includes the pathological conversion of the PrP
C
 into the toxic and infectious 
isoform denoted as prion or PrP
Sc
. PrP
Sc
 faithfully replicates, aggregates and deposits in brain 
parenchyma and is not prone to degradation via cellular proteases [1]. From the infected cell, 
horizontal and vertical transmission can occur, since misfolded proteins are efficiently transmitted to 
the daughter cells and by the intercellular spread [8].  
The transgenic mice lacking Prnp gene are resistant to prion diseases [9] suggesting that the disease 
progression is dependent on a pool of PrP
C
 within the cell that can be replicated. The PrP knockout 
mice show no significant phenotype. Likewise, the conditional Prnp knockout showed no signs of 
neurodegeneration [10]. This focused the design of therapeutic approaches towards the attenuation of 
PrP
C
 [11]. However, a growing body of data reveals potential physiological PrP
C
 functions, including 
its neuroprotective role in the CNS, while the loss of PrP
C
 function renders the cells more susceptible 
to different types of stress [12]. In spite of this, the lack of deleterious effects upon the absence or 
silencing of PrP, observed in relevant animal models, infers a window of opportunity that can be used 
for the treatment aimed at the neutralization or depletion of the PrP
C
. This review will focus on the role 
of prion-specific antibodies in the modulation of PrP biology and the development of related 
therapeutic applications.  
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2. Therapeutic Candidates that Modulate PrP
C
 Expression or Accessibility to Conversion 
A number of drugs have been tested for therapeutic intervention in patients affected by TSEs, but 
none significantly increase the survival of patients [13]. The hypothesis that PrP
C
 is essential for prion 
replication, but dispensable for the host, resulted in two types of anti-prion compounds that target  
PrP
C
 expression. 
First, some drugs have been tested that are considered safe for human health, and possess the 
desired ability to modulate PrP
C
 expression, either by reducing or rearranging its cellular pool. A 
prominent example is suramin [14] and its derivatives which modulate biochemical properties of PrP
C
 
including solubility, its half-life [15] and, according to other studies, internalization rate [16]. Another 
example of a PrP
C
 modulator that inhibits formation of the scrapie isoform is the drug mevinolin [17], 
which has multiple generic names and is used to lower cholesterol [18]. Mevinolin reduces the surface 
expression of PrP
C
 leading to its intracellular accumulation [19]. Tamoxifen, another pharmaceutical [20], 
and its derivative 4-hydroxytamoxifen were recently shown to redirect cholesterol to lysosomes and 
consequently induce PrP
C
 as well as PrP
Sc
 degradation through enhanced lysosomal trafficking and 
degradation [21]. However, a list of chemotherapeutics targeting PrP
C
 expression, PrP
Sc
 expression or 
the conversion, including pentosan polysulfate, quinacrine, amphotericine B and flupirtine, have 
already been tried in clinical trials showing no or modest treatment efficacies [22]. Recently, a 
comprehensive drug screening was undertaken to identify new anti-PrP agents among drugs already 
approved for human use [23]. Screening targeted compounds that decrease PrP
C
 expression. The most 
promising candidate, astemizole, prolonged the survival of prion-infected mice via stimulated 
autophagy [23]. 
The second line of compounds specifically target PrP
C
 and as such their mode of action in principle 
should not affect other aspects of cellular biology, including the cell viability. One straightforward 
approach to specifically decrease PrP
C
 levels is to target the expression of the gene responsible, in 
humans PRNP, either with interfering RNA molecules or by introducing a dominant negative mutant [24]. 
Molecules that bind specifically to PrP
C
 include nucleic acid aptamers and peptide aptamers [25], 
which show inhibitory effect on prion conversion. In addition, a broad range of evidence shows that 
antibodies targeting PrP
C
, as a template for the scrapie prion propagation, are effective in curing 
infected cells [26–29]. Anti-PrPC antibodies and their derivatives represent a range of compounds able 
to reduce availability of the PrP
C
 substrate for conversion; either by minimizing PrP
C
 expression and 
inducing its redistribution from the sites critical for prion conversion or by preventing the formation of 
the molecular complexes between PrP
C
 and PrP
Sc
 and other potential cofactors (Figure 1 and discussed 
below). In addition, antibodies may act as other potential drugs that bind PrP
C
 and tend to stabilize the 
PrP
C
 molecule in order to prevent conversion [11].  
Beyond PrP
C
 many drugs target PrP
Sc
 template. The awareness of the need for combination therapy 
is evolving after the anti-prion drug resistance was confirmed [30] for most promising candidates 
obtained within a comprehensive study of more than 10,000 small molecules able to reduce PrP
Sc
 
content [31]. Recently, a new battery of promising small molecules with the ability to decrease the 
accumulation of PrP
Sc
 was obtained in another comprehensive screening that evaluated their drug 
ability and pharmacokinetic parameters [32]. When targeting PrP
Sc
 template, the aim may be to 
promote degradation, as observed for some branched polyamines [33] or for tyrosine kinase inhibitor 
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STI571, which promotes lysosomal degradation [34]. Alternatively, the aim may be to stabilize fibrils 
as was proposed for congo red [35] or luminescent conjugated polymers [36] in order to reduce the 
spread of low molecular weight oligomers that seem to be particularly infectious and toxic [37,38]. 
Antibodies so far have not been implied in the stabilization of PrP
Sc
, but in principle they could be 
able to do so if they recognized epitopes of the PrP
Sc
 amyloid fibrils (Figure 1). Alternatively, antibodies 
can selectively target misfolded proteins while sparing native, properly folded protein [39–45]. An 
antibody that would bind specifically to PrP
Sc
 could modulate PrP
Sc
 trafficking or inhibit PrP
Sc
 
interaction with other molecules analogously as described for PrP
c
 (Figure 1). Some studies found that 
PrP
Sc
 recognition is a beneficial feature of a curing antibody [46]. However, a significant number of 
curing antibodies do not recognize PrP
Sc
 [28]. In addition, some antibodies that recognize PrP
Sc
 have 
weak curing properties when administrated into in vivo or in vitro settings [27,45,47,48].  
In conclusion, antibodies and their derivatives are on the list of most prominent candidates for  
the treatment of prion diseases [49,50] due to their effectiveness at targeting the PrP
C
 as a reservoir for 
the prion conversion but also because of their potential to act on multiple and diverse levels in the 
prion pathogenesis. 
3. The Role of Antibodies in the Molecular Mechanism of the PrP
C
 to PrP
Sc
 Conversion 
The key process behind prion diseases is the conversion of PrP
C
 into the PrP
Sc
 isoform. In this 
process anti-PrP antibodies represent one of the most promising strategies for the treatment of prion 
diseases ever since they not only reduced, but completely cleared the pre-existing PrP
Sc
 from a culture 
of infected neuroblastoma cells [26,29,51]. However, the molecular mechanisms behind the conversion 
of PrP
C
 into PrP
Sc
 and the role anti-PrP antibodies play remains elusive.  
Regarding some aspects of the antibody-mediated process of clearing PrP
Sc
 a general consensus has 
been reached. There is a direct correlation between the affinity of anti-PrP antibody for the PrP
C
 isoform 
and its potency to cure prion infected cells [27,28,52]. Furthermore, there is no unique epitope in the PrP
C
 
molecule that clears the disease, although not all epitopes are suitable or equally effective [28,47,52–55]. 
Finally, the compartment(s) of prion conversion are still the matter of debate, but the lines of  
evidence [56–61] including the most recent studies [62–65] largely agree that the plasma membrane 
and the membrane trafficking along the endocytic-recycling pathway are prominent sites where PrP
C
 
and PrP
Sc
 reside. Such localization favors the accessibility of both targets to the antibodies and 
warrants the maintenance of the stable antibody-target complexes. The ability of an antibody to 
recognize native PrP
C
 molecules expressed on the plasma membrane may discriminate protective vs. 
non-protective immune responses [66–68]. In many cases, antibodies that have shown significant 
clearing capacities were internalized into the cells [28,52,69,70] suggesting their potential to exhibit 
additional positive effects also along the endocytic pathway. 
Despite the convergence of several important issues of the antibody clearing capacity, there are  
a high number of mechanisms proposed for the function of anti-PrP antibodies. It is evident that  
these molecular mechanisms depend on the antibody epitope and in addition, different mechanisms  
do not necessarily exclude one another. Among them are: steric blocking or modifying the interaction 
of PrP
C
 with PrP
Sc
 [26,52,71]; perturbation of PrP
C
 trafficking, including internalization and 
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degradation [28,52,70,72,73]; PrP sequestration on the cell surface [28,29,52,54]; increase of PrP
C
 
levels in the medium [28,52]; and neutralization of the infectious PrP
Sc
 template [52,72].  
Although relevant for designing immunotherapeutic tools, the characterization of the antibody role 
in PrP
C
 conversion to PrP
Sc
 is still not fully clarified. Thorough understanding of this molecular 
mechanism will contribute to the design of anti-prion therapeutics and to general principles  
of immunotherapy.  
 
Figure 1. Anti-prion protein antibody (Ab) modulation of the PrP
C
 and PrP
Sc
 biology. 
There are no documented Ab effects on the PrP
C
 transcription or translation. Ab effect on 
the immature PrP
C
 is restricted to some intrabodies. (a) Published Ab mediated effects on 
the PrP
C
 trafficking; (b) Other modes of Ab impact on mature PrP
C
 that do not include the 
PrP
C
 trafficking modulation and are not restricted to the specific compartment; (c) Modes 
of Ab action on the PrP
Sc
 cannot be easily separated from the modulation of PrP
C
 because 
the percentage of the PrP
Sc
 in the cell is much lower and most of the Abs that recognize 
Viruses 2014, 6 3724 
 
 
PrP
Sc
 do not discriminate between forms. Not fully confirmed modes of action are noted as 
‘putative’. Undefined cellular compartments are depicted with a dotted line. Full IgGs and 
other recombinant Abs (Figure 2), except for intrabodies, are schematically represented by 
the same Ab symbol. 
 
Figure 2. Conventional and recombinant antibody compounds that have been developed 
against the prion protein. Schematic representation of mouse natural IgG (conventional 
IgG) that is composed of two light chains and two heavy chains linked together with 
disulfide bridges is shown. A variable domain of the conventional antibody that binds to 
the specific antigen is composed of the sequence on the heavy and on the light chain while 
each of these sequences is composed of three complementarity determining regions 
(CDRs). Common IgG fragments generated by enzymatic digestions or by the recombinant 
DNA technique are shown. The natural camelid IgG possess only two chains linked by 
disulfide bridges and each variable domain is composed of a single chain. Intrabodies are 
recombinant intracellular antibodies that are usually engineered to localize to a specific 
cellular compartment. 
4. Active and Passive Immunotherapy Approaches  
Active immunotherapy implies the production of anti-PrP antibodies by the host, mostly following 
vaccination, while in the passive immunotherapy a pre-made therapeutic, an antibody-based 
compound, is delivered directly or by the gene therapy. 
Active immunotherapy suffers from the tolerance of the immune system to develop antibodies to 
the host protein. The prion protein is a native cellular protein and an organism is unlikely to recognize 
the subtle changes attributed to PrP
Sc
 as a threat especially as it is imprinted in the immune system to 
avoid the self-recognition. A number of approaches were undertaken in active immunization studies, 
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including various antigens and adjuvants in order to break the tolerance against PrP [49,50]. The 
evaluation of essential protective immune response properties in different mouse models revealed the 
importance of an antigen to provoke antibodies recognizing cell-surface PrP
C
 [66]. This finding was 
confirmed in the recent study identifying compounds with the best immunogenic potential, in which 
the protection model was further associated with depletion of mature follicular dendritic cells, which 
spread peripheral prion infection [67]. Encouraging results in the generation of host antibodies towards 
PrP
C
 were obtained using PrP monomer peptides, multiple antigenic peptides, full PrPs, proteins 
resembling PrP epitopes or PrP dimers as the antigen of choice, administrated through various vector-, 
protein-, virus- or cell-carriers [49,50,74]. In addition, naturally occurring PrP autoantibodies were 
recently confirmed in cerebrospinal fluid and serum samples of healthy individuals [75]. The approach 
to target the PrP
Sc
 template and at the same time avoid the recognition of abundantly expressed PrP
c
, 
guided the development of the vaccine based on the PrP
Sc
 dominant epitope YYR [40]. The follow up 
studies were focused to (i) exclude the concern that such anti-PrP
Sc
 antibodies might by themselves 
induce the formation of the PrP
Sc
 template and to (ii) drive the anti-PrP antibody response towards 
conformations of PrP mutants associated with genetic types of the disease [76]. The animal studies 
show that still mucosal vaccination seems to be the most effective, although this approach would be 
restricted to preventing oral transmission among animals and human populations at risk [77,78].  
Ubiquitous PrP
C
 expression not only aggravates the natural expansion of anti-PrP antibodies, but 
also the introduction of premade antibodies recognizing PrP
C
 via passive immunotherapeutic approaches 
might lead to severe immune reactions. This concern was alleviated after the groundbreaking study 
showing that co-expression of PrP-specific antibodies with PrP
C
 expressed at physiological levels does 
not induce autoimmune responses or significant changes in various immune cell populations, which 
were still able to respond to other stimuli [71]. At the same time, the substantial anti-PrP antibody 
levels in the serum prevented scrapie pathogenesis after prion inoculation. Another study, based on 
subsequent and continuous passive immunizations initiated immediately following the scrapie inoculation, 
resulted in the prolongation of the incubation period or even prevention of disease, depending on the 
antibody used and the inoculum quantity [79]. The passive immunization attracted further interest after 
it was shown that the application of anti-PrP antibodies suppressed, in some cases even permanently, a 
peripheral prion replication in vivo and that such treatment was successful even after the onset of 
peripheral prion replication, although not after the clinical signs of illness were present [47]. In 
addition, administrated anti-PrP antibodies did not deplete PrP expressing immune cell populations nor 
was evidence for autoimmune reactions found. Recent data showed that in addition to intraventricular 
administration [80], a peripheral administration of antibodies could alleviate the disease progression 
also at the time of clinical onset [81]. The efficacy of the antibody distribution in the cerebella and 
thalami was in the correlation with the prolongation of survival times. Indeed, the delivery of the 
therapeutic to the infected brain is essential and as such new vectors that allow for the better delivery 
of anti-prion protein antibodies into the brain are being envisaged (discussed below, [82–84]). Likewise, 
recombinant antibody-derivatives with improved drug characteristics are being designed (discussed 
below). However, advancements of the numerous passive immunizations in the last decade [49] that 
resulted in more or less significant increase in the resistance to PrP
Sc
, including the prolongation of the 
incubation period and the lifespan of treated animals, have been compromised with their possible 
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neurotoxic effects [55,85]. These effects are still a matter of debate [86], but certainly pose additional 
requests to the design of the antibody-based therapeutics.  
A line of evidence shows how PrP
C
 plays an important role in the pathogenesis of other 
neurodegenerative diseases, such as Alzheimer’s disease (AD) [87]. Among neurodegenerative 
disorders, clinical development of immunotherapeutic strategies to cure AD patients is by far most 
advanced [88]. Unfortunately, active anti-AD immunization trials were stopped due to the severe side 
effects [88] while two phase III trials of anti-β-amyloid monoclonal antibody recently showed that 
passive immunotherapy provokes less alarming side effects, but does not improve clinical outcomes in 
patients with AD [89]. Regardless, new links between distinct neurodegenerative diseases will 
undoubtedly boost the anti-prion immunotherapeutic approaches including the especially relevant topic 
of better understanding of toxic side effects. A prominent example is the recent study on fully 
humanized anti-PrP antibody that was shown to prevent Aβ synaptotoxicity in rats without inducing 
obvious neurotoxicity [90]. As already mentioned, our understanding of the molecular mechanisms 
behind the mode of action of anti-PrP antibodies is insufficient and, correspondingly, multiple 
mechanisms are still proposed for the antibody-mediated plaque removal in AD [88]. The findings 
from the research on fundamental principles driving the immunotherapy of prion illnesses may thus 
provide a breakthrough in our knowledge of the more common neurodegenerative diseases. 
5. Molecular Parameters that Influence the Quality of the Anti-Prion Protein Antibody Effect 
In spite of the continuous progress, the major drawbacks of the passive immunization approach are 
still the (i) unfavorable pharmacokinetic of drugs; (ii) high amount of the drugs needed; (iii) and the 
inability of drugs to cross the blood-brain barrier (BBB) if they are not focused on the inhibition of 
peripheral prion replication and must access the central nervous system (CNS); all the above probably 
lead to limited success as therapeutics in vivo. Last but not the least; (iv) there is a concern that anti-PrP
C
 
antibodies might be neurotoxic. To that aim different recombinant antibody derivatives with different 
properties have been designed. Still, clinical immunotherapy trials in the neurodegenerative diseases 
used conventional full length IgG, although in the recombinant, humanized form [89]. In spite of the 
general complaint of IgG low potential to reach the CNS, in vivo studies showed that autoantibodies 
against Aβ can in fact cross the BBB [49] and peripheral administration of humanized form of IgG 
reached therapeutically active concentrations to prevent Aβ synaptotoxicity [90]. 
Since the generation of the first immunogens, numerous anti-PrP antibodies and antibody 
compounds have been developed, at first polyclonal [91] and later mostly by the immunization of 
Prnp°
/
° mice [9]. Interestingly, the first antibodies obtained upon the immunization of Prnp°
/
° mice 
were generated in the active form of the recombinant antigen-binding fragment, Fab (fragment 
antigen-binding), by the phage display technology due to the instability of initially acquired hybridoma 
cell lines secreting conventional monoclonal antibodies (Figure 2) [92]. Series of conventional 
antibodies have been raised since then, with promising candidates able to cure PrP
Sc
 in vitro with half 
maximal inhibitory concentration of PrP
Sc
 (IC50) far below 1 μM [50]. The process of developing new 
panels of anti-PrP antibodies is still in progress [45,93–96]. A study aimed at characterizing the 
pharmacokinetic properties of anti-PrP antibodies with curing properties in vitro showed that their 
Viruses 2014, 6 3727 
 
 
curing capacity in vivo is associated with intrinsic pharmacokinetic properties rather than their isotype, 
epitope or affinity [97]. 
Recombinant Fab fragments (Figure 2) successfully cleared prion infectivity from cell cultures of 
infected cells [26]. Although a difference between polyclonal IgG molecules and corresponding Fab 
fragments in their capacity to inhibit prion replication in infected cells was observed [51], a 
comparison of several full IgGs and their Fab fragments showed that they retain similar binding 
properties and similar curing capacity [98]. The Fab fragments should be less prone to induce 
neurotoxicity, but this is still disputed. Namely, two studies showing neurotoxic side effects upon the 
antibody injection into the brain agreed that antibody mediated neurotoxicity was not mediated by its 
Fc (fragment crystallizable) fragment, but by triggering PrP
C
 and that toxicity was dependent on the 
dosage of the antibody treatment [55,85]. Unfortunately, these studies did not reach agreement about 
other antibody parameters that should be taken into consideration during drug development nor on the 
molecular mechanism triggering downstream neurotoxic effects. The first study proposed that the 
divalent antibody form is responsible for crosslinking and triggering PrP
C
 molecules leading to cell 
apoptosis [85], while the other proposed that the antibody epitope within a particular PrP
C
 domain is 
detrimental for calpain activation [55]. The latter study showed no significant differences between the 
monovalent and divalent forms of the antibodies tested. Fortunately, in both studies some antibodies 
escaped the neurotoxic phenotype. Taken together with studies showing no deleterious effects upon the 
comparable antibody administration [54,80,86], emphasizes that generalizations about the toxicity of 
antibodies should be avoided and strongly suggests that a therapeutic window must exist. Certainly, 
Fab fragments have shorter circulating half-lives, but improved production opportunities via recombinant 
prokaryotic expression and enhanced capacity of penetrating into the brain [98,99] when compared to 
the full IgGs. However, in respect to these later advantages, smaller recombinant compounds are even 
more promising (Figure 2, [100]) and in addition to the Fabs and IgGs, many smaller monovalent 
compounds have been designed. 
The limitations of full IgGs: the poor influx into CNS, the putative toxicity and the complex 
assembly; prompted studies aimed at generation of more potent recombinant proteins on the backbone 
of antibodies with desirable affinity characteristics. In line with that, recombinant anti-PrP scFvs 
(single-chain variable fragments, Figure 2) were designed and verified in neurodegenerative disease 
models [101]. Here, the scFvs retained the ability to clear the PrP
Sc
 infected cell cultures [68,84,102–104]. 
Recently, a humanized anti-PrP
Sc
 scFv has been produced [105]. The acknowledged advantage of the 
scFvs is their expression, suitable for large scale production in the periplasmic space of E. coli. In 
parallel, several eukaryotic cell lines secreting scFvs have been established [68,102,103]. One of the 
trasnsfectants was made on the background of immortalized microglia, acknowledged brain-engraftable 
cells that resulted in a short prolongation of the survival times in mice [103]. Indeed, the main 
advantage of the scFv is its single polypeptide sequence suitable for the gene transfer-based passive 
immunization, the approach in which the antibody is not delivered by the direct application, but by a 
corresponding gene encoding the antibody later synthesized by the host. The most recognized vectors 
for the delivery of these antibody genes, possessing high transduction efficiency and allowing 
intracerebral spread, are adeno-associated virus (AAV) based vectors. Two studies on vector types 
AAV2 and AAV9, both carrying genes for anti-PrP scFv, have resulted in a delay in the onset of 
clinical signs of disease, prolonged survival time, milder neuropathological changes, reduced PrP
Sc
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burden in the brain and, importantly, no inflammatory or neurotoxic effects together with prominent 
neuronal transduction efficiency and spread [82,83]. However, these beneficial outcomes were not all 
significant and both groups in their experimental model used intracerebral injection of the vectors 
followed by intraperitoneal challenge at expected peak of the scFv gene expression. A study aimed to 
design molecules and delivery mode that might function both peripherally and within the brain, thus 
affecting both sites of prion replication, explored the potential of lentiviral and AAV vectors encoding 
anti-PrP scFv [84]. In cell culture models of PrP
Sc
 clearance the lentiviral construct represented a more 
efficient delivery system compared to AAV. The scFv antibody format is also prevalent for the 
intracellular antibody (intrabody) expression [73]. These recombinant antibodies are engineered to 
localize to a specific cellular compartment. The Anti-PrP scFv with ER retention signal successfully 
retained PrP
C
 in the ER and prevented PrP
Sc
 formation in the corresponding transfected cell lines, 
while the secretory version of the same intrabody mediated re-routing of PrP
C
 to proteasome as well as 
impairment of PrP
C
 association to exosomes [73]. An interesting scFv was recently obtained by fusing 
anti-PrP
Sc
 antibody variable domains with an advanced linker, cell-penetrating peptide (CPP), 
penetratin [106]. Upon administration in the mouse tail vein, the scFv without penetratin mainly 
stained the endothelial cells of brain veins, while the penetratin-scFv was transported through the BBB 
into the brain cells. However, an unexpected localization into the nuclei was observed that might 
necessitate additional modifications of this promising recombinant antibody. 
In addition to the scFvs, other, smaller antibody forms have been envisaged. To that aim, camelid 
antibodies are of great interest, since they lack light chains and consequently possess a genuine single 
chain variable domain. Thus, corresponding recombinant antibody fragments, called nanobodies, are 
significantly smaller than scFvs obtained from the conventional antibodies (Figure 2). The ability of 
recombinant camelid antibody fragments to abolish prion replication in infected cell lines [72,96] and 
to diffuse into the brain parenchyma upon peripheral administration was confirmed [69]. A variable 
domain of the conventional antibody is composed of the sequence on the heavy and on the light chain 
and each of these sequences is composed of three complementarity determining regions (CDRs,  
Figure 2). The heavy chain of the anti-PrP antibody, combined with unrelated light chains, retained the 
capacity to prevent prion pathogenesis upon peripheral scrapie challenge [71]. Furthermore, a peptide 
mimicking only the third CDR of the anti-PrP heavy chain domain (CDR3H) showed anti-prion 
capacity in vitro [104].  
Many promising anti-PrP antibody compounds have been produced so far. The main concern 
remains that, unless an artificial amount of an antibody is supplied to the site of infection, the reduction 
of the PrP
c
 content in patients might only postpone and not prevent the illness [107]. The fact that a 
small amount of PrP
C
 is enough for the productive replication underscores the hypothesis [108]. Alike, 
the need for the improvement of diagnostic tools that could pinpoint the illness at the earliest stage 
goes hand in hand with the need to optimize the infection::antibody ratio. Most of the administrated 
antibody compounds, including the full IgGs, do not have suitable characteristics to cure the infection 
in brain, but at the same time the gene-based delivery routes are still providing only a short term 
supply [82,83,103]. Although our future might decide on the gene therapy with the smallest possible 
antibody based drugs, currently in the treatment of neurodegenerative diseases conventional 
humanized IgG approach is still mainstream. 
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6. Authors’ Perspective 
For more than a decade, the scientific community has been trying to envisage innovative 
therapeutics based on the anti-prion protein antibodies and new vaccines able to break immune 
tolerance against the prion protein. A remarkable pool of structural data and a considerable list of 
antibodies and recombinant antibody-forms generated to a single protein, the prion protein, offer a 
unique possibility to explore the fundamental premises of the immunotherapy. Unfortunately, few 
studies compared the original antibodies and their recombinant derivatives or a palette of recombinant 
antibodies recognizing the same epitope in thorough in vitro or in vivo studies. The influence of the 
size/form/valency/posttranslational modification of the antibody derivatives on the fundamental 
molecular mechanism triggered by their binding to the PrP molecules is still elusive. Among others, 
this includes the factor of antibody size on steric hindrance and blocking of PrP
C
 conversion, the 
capacity of different derivatives to be internalized into the cells, the importance of their ability to 
crosslink the PrP molecules and induce or block endocytosis, the antibody-PrP complexes’ stability 
and dissociation of PrP molecules within various organelles and the molecular determinants triggering 
neurotoxic effects. In addition, the antibody glycosylation is very complex and its influence on the 
subtle differences in the antibody mode of action will be an interesting target for examination. Once 
rules that are more general with respect to the molecular mechanisms and the drug characteristics 
influencing PrP
Sc
 clearance are established, it will be easier to manipulate the functional and curative 
anti-PrP antibody properties. Such scientific outcomes will contribute to the understanding of general 
principles of recombinant antibody design and immunotherapy. 
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